EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.
The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and tissue-based phenotypes predictive of therapeutic response.
Three-quarters of people who respond well to the newest types of biologics for psoriasis can safely reduce their dosage, often even by half.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
